ArticleOncotarget2016

MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy.

XiaoRong Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.